O	0	10	Comparison
O	11	13	of
B-intervention	14	20	ductal
I-intervention	21	27	lavage
O	28	31	and
B-control	32	38	random
I-control	39	50	periareolar
I-control	51	55	fine
I-control	56	62	needle
I-control	63	73	aspiration
O	74	76	as
O	77	83	tissue
O	84	95	acquisition
O	96	103	methods
O	104	106	in
O	107	112	early
O	113	119	breast
O	120	126	cancer
O	127	137	prevention
O	138	144	trials
O	144	145	.

O	146	151	Short
O	151	152	-
O	152	156	term
O	157	162	phase
O	163	164	I
O	165	168	and
O	169	174	phase
O	175	177	II
O	178	184	breast
O	185	191	cancer
O	192	202	prevention
O	203	209	trials
O	210	217	require
O	218	224	tissue
O	225	236	acquisition
O	237	239	at
O	240	248	baseline
O	249	252	and
O	253	258	after
O	259	271	intervention
O	272	274	to
O	275	283	evaluate
O	284	294	modulation
O	295	297	of
O	298	307	potential
O	308	318	biomarkers
O	318	319	.

O	320	329	Currently
O	330	334	used
O	335	341	tissue
O	342	353	acquisition
O	354	361	methods
O	362	369	include
O	370	376	ductal
O	377	383	lavage
O	384	385	(
O	385	387	DL
O	387	388	)
O	388	389	,
O	390	396	random
O	397	408	periareolar
O	409	413	fine
O	414	420	needle
O	421	431	aspiration
O	432	433	(
O	433	438	RPFNA
O	438	439	)
O	439	440	,
O	441	444	and
O	445	449	core
O	450	456	needle
O	457	463	biopsy
O	463	464	.

O	465	468	The
O	469	476	optimum
O	477	483	method
O	484	486	to
O	487	495	retrieve
O	496	504	adequate
O	505	512	samples
O	513	516	and
O	517	520	the
O	521	525	most
O	526	534	accepted
O	535	541	method
O	542	544	by
O	545	550	study
O	551	563	participants
O	564	566	is
O	567	570	not
O	571	576	known
O	576	577	.

O	578	580	We
O	581	589	compared
O	590	595	RPFNA
O	596	599	and
O	600	602	DL
O	603	605	as
O	606	612	breast
O	613	619	tissue
O	620	631	acquisition
O	632	639	methods
O	640	643	for
O	644	649	short
O	649	650	-
O	650	654	term
O	655	661	breast
O	662	668	cancer
O	669	679	prevention
O	680	686	trials
O	687	689	by
O	690	700	evaluating
O	701	707	sample
O	708	716	adequacy
O	717	720	and
O	721	733	tolerability
O	734	736	in
O	737	745	subjects
O	746	749	who
O	750	762	participated
O	763	765	in
O	766	769	two
O	770	781	prospective
O	782	787	phase
O	788	790	II
O	791	797	breast
O	798	804	cancer
O	805	815	prevention
O	816	822	trials
O	822	823	.

B-total-participants	824	830	Eighty
I-total-participants	830	831	-
I-total-participants	831	834	six
B-eligibility	835	840	women
I-eligibility	841	843	at
I-eligibility	844	853	increased
I-eligibility	854	858	risk
I-eligibility	859	862	for
I-eligibility	863	869	breast
I-eligibility	870	876	cancer
O	877	881	were
O	882	890	included
O	891	893	in
O	894	898	this
O	899	904	study
O	905	908	and
O	909	918	underwent
O	919	927	baseline
O	928	930	DL
O	931	934	and
O	935	940	RPFNA
O	940	941	.

O	942	946	High
O	947	951	risk
O	952	955	was
O	956	963	defined
O	964	966	as
O	967	973	having
O	974	975	a
O	976	977	5
O	977	978	-
O	978	982	year
O	983	987	Gail
O	988	993	score
O	994	996	of
O	997	998	>
O	998	999	1
O	999	1000	.
O	1000	1002	67
O	1002	1003	%
O	1004	1006	or
O	1007	1008	a
O	1009	1016	history
O	1017	1019	of
O	1020	1028	atypical
O	1029	1040	hyperplasia
O	1041	1042	(
O	1042	1044	AH
O	1044	1045	)
O	1045	1046	,
O	1047	1054	lobular
O	1055	1064	carcinoma
O	1064	1065	,
O	1066	1068	or
O	1069	1075	breast
O	1076	1082	cancer
O	1082	1083	.

O	1084	1090	Median
O	1091	1094	age
O	1095	1098	was
B-age	1099	1101	54
I-age	1101	1102	.
I-age	1102	1103	5
I-age	1104	1109	years
O	1110	1111	(
O	1111	1116	range
O	1116	1117	,
O	1118	1120	39
O	1120	1121	-
O	1121	1123	75
O	1124	1129	years
O	1129	1130	)
O	1130	1131	;
O	1132	1134	75
O	1134	1135	%
O	1136	1138	of
O	1139	1142	the
O	1143	1148	women
O	1149	1153	were
O	1154	1168	postmenopausal
O	1168	1169	.

O	1170	1175	About
O	1176	1178	51
O	1178	1179	%
O	1180	1182	of
O	1183	1186	the
O	1187	1192	women
O	1193	1200	yielded
O	1201	1207	nipple
O	1208	1218	aspiration
O	1219	1224	fluid
O	1224	1225	,
O	1226	1229	and
O	1230	1236	breast
O	1237	1242	fluid
O	1243	1250	samples
O	1251	1254	via
O	1255	1257	DL
O	1258	1262	were
O	1263	1272	retrieved
O	1273	1275	in
O	1276	1278	73
O	1278	1279	%
O	1280	1282	of
O	1283	1288	these
O	1289	1297	subjects
O	1297	1298	.

O	1299	1301	Of
O	1302	1307	these
O	1308	1315	samples
O	1315	1316	,
O	1317	1319	71
O	1319	1320	%
O	1321	1325	were
O	1326	1334	adequate
O	1335	1342	samples
O	1343	1344	(
O	1344	1351	greater
O	1352	1356	than
O	1357	1359	10
O	1360	1370	epithelial
O	1371	1376	cells
O	1376	1377	)
O	1377	1378	.

O	1379	1386	However
O	1386	1387	,
O	1388	1392	when
O	1393	1396	the
O	1397	1403	entire
O	1404	1410	cohort
O	1411	1414	was
O	1415	1425	considered
O	1425	1426	,
O	1427	1431	only
O	1432	1434	31
O	1434	1435	%
O	1436	1438	of
O	1439	1442	the
O	1443	1451	subjects
O	1452	1455	had
O	1456	1464	adequate
O	1465	1472	samples
O	1472	1473	.

O	1474	1479	RPFNA
O	1480	1483	was
O	1484	1488	also
O	1489	1498	attempted
O	1499	1501	in
O	1502	1505	all
O	1506	1514	subjects
O	1514	1515	,
O	1516	1519	and
O	1520	1526	sample
O	1527	1536	retrieval
O	1537	1541	rate
O	1542	1545	was
O	1546	1549	100
O	1549	1550	%
O	1550	1551	.

O	1552	1555	Out
O	1556	1558	of
O	1559	1564	these
O	1564	1565	,
O	1566	1568	96
O	1568	1569	%
O	1570	1572	of
O	1573	1576	the
O	1577	1585	subjects
O	1586	1589	had
O	1590	1598	adequate
O	1599	1606	samples
O	1606	1607	.

O	1608	1610	In
O	1611	1613	DL
O	1614	1621	samples
O	1621	1622	,
B-outcome	1623	1625	AH
I-outcome	1626	1630	rate
O	1631	1634	was
B-iv-bin-percent	1635	1636	3
I-iv-bin-percent	1636	1637	.
I-iv-bin-percent	1637	1638	7
I-iv-bin-percent	1638	1639	%
O	1640	1643	was
O	1644	1647	and
B-outcome	1648	1659	hyperplasia
I-outcome	1660	1661	(
I-outcome	1661	1662	H
I-outcome	1662	1663	)
I-outcome	1664	1668	rate
O	1669	1672	was
B-iv-bin-percent	1673	1675	11
I-iv-bin-percent	1675	1676	.
I-iv-bin-percent	1676	1677	1
I-iv-bin-percent	1677	1678	%
O	1678	1679	.

O	1680	1682	In
O	1683	1688	RPFNA
O	1689	1696	samples
O	1696	1697	,
B-outcome	1698	1700	AH
I-outcome	1701	1705	rate
O	1706	1709	was
B-cv-bin-percent	1710	1712	12
I-cv-bin-percent	1712	1713	.
I-cv-bin-percent	1713	1714	9
I-cv-bin-percent	1714	1715	%
O	1715	1716	,
O	1717	1720	and
B-outcome	1721	1722	H
I-outcome	1723	1727	rate
O	1728	1731	was
B-cv-bin-percent	1732	1734	24
I-cv-bin-percent	1734	1735	.
I-cv-bin-percent	1735	1736	7
I-cv-bin-percent	1736	1737	%
O	1737	1738	.

O	1739	1747	Cytology
O	1748	1756	findings
O	1757	1759	in
O	1760	1765	RPFNA
O	1766	1773	samples
O	1774	1784	correlated
O	1785	1789	with
O	1790	1793	age
O	1793	1794	,
O	1795	1805	menopausal
O	1806	1812	status
O	1812	1813	,
O	1814	1817	and
O	1818	1824	breast
O	1825	1831	cancer
O	1832	1836	risk
O	1837	1845	category
O	1846	1847	(
O	1847	1855	previous
O	1856	1863	history
O	1864	1866	of
O	1867	1874	lobular
O	1875	1884	carcinoma
O	1885	1887	in
O	1888	1892	situ
O	1892	1893	)
O	1893	1894	.

O	1895	1899	Both
O	1900	1910	procedures
O	1911	1915	were
B-outcome	1916	1920	well
I-outcome	1921	1930	tolerated
O	1930	1931	,
O	1932	1935	and
B-outcome	1936	1938	no
I-outcome	1939	1952	complications
O	1953	1961	occurred
O	1962	1967	among
O	1968	1980	participants
O	1980	1981	.

O	1982	1993	Considering
O	1994	1998	that
O	1999	2002	the
O	2003	2007	main
O	2008	2011	end
O	2012	2017	point
O	2018	2021	for
O	2022	2027	short
O	2027	2028	-
O	2028	2032	term
O	2033	2043	prevention
O	2044	2050	trials
O	2051	2053	is
O	2054	2057	the
O	2058	2068	modulation
O	2069	2071	of
O	2072	2082	biomarkers
O	2082	2083	,
O	2084	2086	it
O	2087	2089	is
O	2090	2099	important
O	2100	2102	to
O	2103	2111	optimize
O	2112	2120	adequate
O	2121	2127	sample
O	2128	2139	acquisition
O	2139	2140	;
O	2141	2150	therefore
O	2150	2151	,
O	2152	2157	RPFNA
O	2158	2160	is
O	2161	2162	a
O	2163	2167	more
O	2168	2177	practical
O	2178	2184	option
O	2185	2188	for
O	2189	2195	future
O	2196	2201	phase
O	2202	2203	I
O	2204	2207	and
O	2208	2210	II
O	2211	2217	breast
O	2218	2224	cancer
O	2225	2235	prevention
O	2236	2242	trials
O	2243	2251	compared
O	2252	2256	with
O	2257	2259	DL
O	2259	2260	.
